Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo.
Bottom Line: Busulfan has been widely used to treat CML.Moreover, a series of loss-of-function and gain-of-function experiments further indicated that busulfan may have its anti-osteosarcoma effect by upregulating the microRNA-200 (miR-200) family which subsequently downregulated its target genes ZEB1 and ZEB2.Taken together, our data suggest that busulfan may have an anti-osteosarcoma effect through downregulating ZEB1 and ZEB2 through activating the miR-200 family, highlighting a possibility of using busulfan as a novel therapy for osteosarcoma.
Affiliation: 169th Hospital, School of Medicine, Hunan Normal University, Changsha, China.Show MeSH
Related in: MedlinePlus
Mentions: All five members of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) can inhibit epithelial–mesenchymal transition through activating E-cadherin transcription repressors ZEB1 and ZEB2. Thus, we measured the miRNA expression levels in U2OS and MG-63 cells. We found that the five members in the miRNA-200 family were all upregulated after busulfan treatment in both cell lines (Fig. 2a).
Affiliation: 169th Hospital, School of Medicine, Hunan Normal University, Changsha, China.